Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation.
Pasvolsky O, Marcoux C, Wang Z, Milton DR, Pal B, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Syed N, Aljawai Y, Lee HC, Patel KK, Becnel MR, Ye C, Kebriaei P, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Pasvolsky O, et al. Among authors: milton dr. Transplant Cell Ther. 2024 Dec 31:S2666-6367(24)00841-8. doi: 10.1016/j.jtct.2024.12.023. Online ahead of print. Transplant Cell Ther. 2024. PMID: 39746546
Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant.
Marcoux C, Pasyar S, Milton DR, Khan HN, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Neupane N, Lee HC, Patel KK, Tang G, Aljawai Y, Kebriaei P, Thomas SK, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH, Pasvolsky O. Marcoux C, et al. Among authors: milton dr. Br J Haematol. 2024 Nov 28. doi: 10.1111/bjh.19937. Online ahead of print. Br J Haematol. 2024. PMID: 39610225 No abstract available.
Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation.
Pasvolsky O, Marcoux C, Milton DR, Pal B, Tanner MR, Bashir Q, Srour S, Lee J, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Kebriaei P, Becnel MR, Lee HC, Patel KK, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Pasvolsky O, et al. Among authors: milton dr. Blood Cancer J. 2024 Oct 31;14(1):189. doi: 10.1038/s41408-024-01165-w. Blood Cancer J. 2024. PMID: 39482325 Free PMC article.
Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma With Deletion 17p.
Marcoux C, Pasvolsky O, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Lee HC, Patel KK, Kebriaei P, Ahmed A, Aljawai Y, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Marcoux C, et al. Among authors: milton dr. Transplant Cell Ther. 2024 Oct 22:S2666-6367(24)00728-0. doi: 10.1016/j.jtct.2024.10.011. Online ahead of print. Transplant Cell Ther. 2024. PMID: 39448031
Signet ring cells and conditional survival after trimodality therapy for esophageal adenocarcinoma.
Mitchell KG, Feldman H, Milton DR, Antonoff MB, Hofstetter WL, Rice DC, Vaporciyan AA, Lin R, Thall PF, Rajaram R; and other members of the MD Anderson Cancer Center Esophageal Adenocarcinoma Study Group. Mitchell KG, et al. Among authors: milton dr. J Surg Oncol. 2024 Sep;130(3):428-434. doi: 10.1002/jso.27774. Epub 2024 Jul 14. J Surg Oncol. 2024. PMID: 39004940
Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades.
Pasvolsky O, Marcoux C, Dai J, Milton DR, Tanner MR, Syed N, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Lee HC, Gaballa MR, Patel KK, Kebriaei P, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Pasvolsky O, et al. Among authors: milton dr. Transplant Cell Ther. 2024 Aug;30(8):772.e1-772.e11. doi: 10.1016/j.jtct.2024.06.001. Epub 2024 Jun 7. Transplant Cell Ther. 2024. PMID: 38852784
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation.
Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Kebriaei P, Aljawai Y, Khan HN, Lee HC, Ye C, Patel KK, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Pasvolsky O, et al. Among authors: milton dr. Blood Cancer J. 2024 May 17;14(1):82. doi: 10.1038/s41408-024-01062-2. Blood Cancer J. 2024. PMID: 38760362 Free PMC article.
Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation.
Alzahrani K, Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH. Alzahrani K, et al. Among authors: milton dr. Br J Haematol. 2024 May;204(5):1944-1952. doi: 10.1111/bjh.19384. Epub 2024 Mar 6. Br J Haematol. 2024. PMID: 38448009
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial.
Khouri IF, Alzahrani K, Kantarjian H, Milton DR, Gulbis AM, Sasaki K, Jain N, Short NJ, Kadia T, Daher M, Rafei H, Im JS, Marin D, Olson AL, Popat U, Qazilbash M, Ramdial J, Rondon G, Srour S, Kebriaei P, Shpall E, Champlin R, Jabbour EJ. Khouri IF, et al. Among authors: milton dr. Am J Hematol. 2024 May;99(5):836-843. doi: 10.1002/ajh.27254. Epub 2024 Feb 23. Am J Hematol. 2024. PMID: 38400519 Clinical Trial.
132 results